The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Business
  • Construction
  • Marketing
  • Health
  • Entertainment

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
  • Detained at 95: South Korea's Prosecution of a Religious Leader Draws International Alarm
  • UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Kolbus Introduces the Next Step in Casemaking Efficiency
  • Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
  • Sounds of LA County: 27 Parks.108 Concerts. One County
  • Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure
  • Los Angeles' Best Food: Food Journal Magazine Examines the Trends Shaping the City's Dining Scene
  • Landmark Construction Expands Glass, Glazing, and Commercial Remodeling Services Across Los Angeles County and Surrounding Areas
  • Imagen Golf Announces Strategic Partnership with The Back Nine of Yardley to Deliver World-Class Indoor Golf Instruction
  • Jazzin' On Ridge Returns for Its 6th Annual Celebration of Music, Culture, and Community
  • ENTOUCH Named Top 100 Inspiring Workplaces in North America for Third Consecutive Year
  • Rebecca L. Francis Receives Pennsylvania's Most Influential Leaders Award
  • Pulse Wave is where moments become movements
  • Michigan's Plane Crash Data Points Away from Big Airports
  • 2iG Solutions Launches MGA Insight, Bringing AI-Powered Business Intelligence to Managing General Agents
  • A Better Way to Find a Real Estate Agent Is Coming Soon
  • Talentica Software Earns a Place Among India's Top 100 Great Mid-size Workplaces 2026
  • 4-Week Search for 2 True "Philly Girls" Starts July 8th 2026
  • Socialhose Launches TikTok Investigator, a Platform for Investigating TikTok Live
  • David Pedrol named Managing Director in Indonesia
  • AutomationIQ Launches to Bring Enterprise-Grade AI Automation to Local and Mid-Market Businesses
  • Texas Hospitals & Their Patients Describe Two Very Different Healthcare Systems, New Social Knowing
  • DEPIN Studios Sees Surge in Demand After AI Gaming Launch
  • Discard Junk Removal Named #1 Junk Removal Company in Sacramento Out of 189 Businesses Evaluated
  • J&J Exterminating Mourns the Passing of Founder Bobby John Sr

Popular on PennZone

  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • Brilliant Minds to Gather in Fort Worth for National Mensa Event
  • West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook
  • Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
  • The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
  • Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
  • Haven Media Solutions Offers Web Design and PPC Services in Atlanta GA
  • Beemok Hospitality Collection And KLH Group Announce Preferred Partnership

Similar on PennZone

  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us